Scientific publications
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis
Sergio Ortiz-Espinosa 1 , Xabier Morales 2 , Yaiza Senent 1 , Diego Alignani 3 , Beatriz Tavira 4 , Irati Macaya 5 , Borja Ruiz 5 , Haritz Moreno 5 , Ana Remírez 6 , Cristina Sainz 6 , Alejandro Rodriguez-Pena 2 , Alvaro Oyarbide 2 , Mikel Ariz 2 , Maria P Andueza 7 , Karmele Valencia 8 , Alvaro Teijeira 9 , Kai Hoehlig 10 , Axel Vater 10 , Barbara Rolfe 11 , Trent M Woodruff 11 , Jose Maria Lopez-Picazo 12 , Silvestre Vicent 13 , Grazyna Kochan 14 , David Escors 14 , Ignacio Gil-Bazo 15 , Jose Luis Perez-Gracia 16 , Luis M Montuenga 13 , John D Lambris 17 , Carlos Ortiz de Solorzano 18 , Fernando Lecanda 6 , Daniel Ajona 19 , Ruben Pio 8
Abstract
Myeloid-derived suppressor cells (MDSCs) play a major role in cancer progression. In this study, we investigated the mechanisms by which complement C5a increases the capacity of polymorphonuclear MDSCs (PMN-MDSCs) to promote tumor growth and metastatic spread.
Stimulation of PMN-MDSCs with C5a favored the invasion of cancer cells via a process dependent on the formation of neutrophil extracellular traps (NETs). NETosis was dependent on the production of high mobility group box 1 (HMGB1) by cancer cells.
Moreover, C5a induced the surface expression of the HMGB1 receptors TLR4 and RAGE in PMN-MDSCs. In a mouse lung metastasis model, inhibition of C5a, C5a receptor-1 (C5aR1) or NETosis reduced the number of circulating-tumor cells (CTCs) and the metastatic burden. In support of the translational relevance of these findings, C5a was able to stimulate migration and NETosis in PMN-MDSCs obtained from lung cancer patients.
Furthermore, myeloperoxidase (MPO)-DNA complexes, as markers of NETosis, were elevated in lung cancer patients and significantly correlated with C5a levels.
In conclusion, C5a induces the formation of NETs from PMN-MDSCs in the presence of cancer cells, which may facilitate cancer cell dissemination and metastasis.
CITATION Cancer Lett. 2022 Mar 31;529:70-84.
doi: 10.1016/j.canlet.2021.12.027. Epub 2021 Dec 28.
![](/.resources/ModuloCUN/resources/img/publicaciones/icono-destacado-investigadores.png)
Our authors
![Xabier Morales. Plataforma Imagen. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/plataformas/imagen/xabier-morales-urteaga/jcr:content/xabier-morales-urteaga.jpg)
![Yaiza Senent. Programa Tumores Sólidos. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/yaiza-senent-valero/jcr:content/yaiza-senent-valero.jpg)
![Diego Alignani. Plataforma Citometría. Cima Universidad de Navarra](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/plataformas/citometria/diego-alignani/jcr:content/diego-alignani.jpg)
![Beatriz Tavira. Tumores sólidos. Cima Universidad de Navarra](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/beatriz-tavira-iglesias/jcr:content/beatriz-tavira-iglesias.jpg)
![Irati Macaya. Programa Tumores Sólidos. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/irati-macaya-erro/jcr:content/irati-macaya-erro.jpg)
![Borja Ruiz Fernández de Córdoba. Programa Tumores Sólidos. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/borja-ruiz-fernanzdez/jcr:content/borja-ruiz-fernanzdez.jpg)
![Haritz Moreno. Programa Tumores Sólidos. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/hartiz-moreno-moreno/jcr:content/hartiz-moreno-moreno.jpg)
![Ana Remírez. Programa Tumores Sólidos. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/ana-remirez-sanz-acedo/jcr:content/ana-remirez-sanz-acedo.jpg)
![Cristina Sáiz. Programa Tumores Sólidos. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/cristina-saiz-zubieta/jcr:content/cristina-saiz-zubieta.jpg)
![Alejandro Rodríguez Pena. Programa Tumores Sólidos. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/alejandro-rodriguez-pena/jcr:content/alejandro-rodriguez-pena.jpg)
![Karmele Valencia Leoz. Programa Tumores Sólidos. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/karmele-valencia-leoz/jcr:content/karmele-valencia-leoz.jpg)
![Daniel Ajona. Programa Tumores Sólidos. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/tumores-solidos/daniel-ajona-martinez-polo/jcr:content/daniel-ajona-martinez-polo.jpg)